Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 10;104(11):e213689.
doi: 10.1212/WNL.0000000000213689. Epub 2025 May 16.

Status Epilepticus Protocol Variation Across Accredited National Association of Epilepsy Centers Members

Collaborators, Affiliations

Status Epilepticus Protocol Variation Across Accredited National Association of Epilepsy Centers Members

Laura K Lamberta et al. Neurology. .

Abstract

Objectives: Status epilepticus (SE) is a neurologic emergency that requires urgent recognition and medical management. SE management remains heterogeneous across centers.

Methods: We analyzed SE treatment protocols from level 3 and level 4 epilepsy centers. Discrete data including stabilization measures, timing of treatment phases, medications, doses, and routes of administration were collected from each protocol and described using frequency for categorical variables and median for continuous variables. The distribution of treatment times and dosing were compared with the AES guideline.

Results: A total of 256 SE treatment protocols were included. Only 66% of SE protocols detailed treatment times. Doses below recommendations occurred in 4% of protocols for initial benzodiazepine (BZD) and 14% for first non-BZD medications. Infusion therapy was outlined in 61% of protocols.

Discussion: Despite the importance of timeliness in SE management, one third of institutional protocols did not specify treatment times. This analysis of US hospital inpatient SE protocols provides expert opinion regarding infusion therapy management and highlights gaps and targets for improvement in SE treatment.

PubMed Disclaimer

Conflict of interest statement

The authors report no relevant disclosures. Go to Neurology.org/N for full disclosures.

Figures

Figure 1
Figure 1. Institutional Goal Status Epilepticus Treatment Times Across 3 Therapeutic Phases
Figure 2
Figure 2. Median Status Epilepticus Protocol Medication Dosing for Each Management Phase
BZD = benzodiazepine; DZP = diazepam; fosPHT = fosphenytoin; IM = intramuscular; IN = intranasal; IV = intravenous; LCS = lacosamide; LEV = levetiracetam; LZP = lorazepam; max = maximum; MDZ = midazolam; PHB = phenobarbital; PR = per rectal; VPA = valproic acid.

Similar articles

References

    1. Trinka E, Cock H, Hesdorffer D, et al. . A definition and classification of status epilepticus—report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515-1523. doi:10.1111/epi.13121 - DOI - PubMed
    1. Trinka E, Rainer LJ, Granbichler CA, Zimmermann G, Leitinger M. Mortality, and life expectancy in epilepsy and status epilepticus—current trends and future aspects. Front Epidemiol. 2023;3:1081757. doi:10.3389/fepid.2023.1081757 - DOI - PMC - PubMed
    1. Gaínza-Lein M, Fernández IS, Ulate-Campos A, Loddenkemper T, Ostendorf AP. Timing in the treatment of status epilepticus: from basics to the clinic. Seizure. 2019;68:22-30. doi:10.1016/j.seizure.2018.05.021 - DOI - PubMed
    1. Silbergleit R, Lowenstein D, Durkalski V, Conwit R, Neurological Emergency Treatment Trials NETT Investigators. RAMPART (Rapid Anticonvulsant Medication Prior to Arrival Trial): a double-blind randomized clinical trial of the efficacy of intramuscular midazolam versus intravenous lorazepam in the prehospital treatment of status epilepticus by paramedics. Epilepsia. 2011;52(suppl 8):45-47. doi:10.1111/j.1528-1167.2011.03235.x - DOI - PMC - PubMed
    1. Chamberlain JM, Kapur J, Shinnar S, et al. . Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet. 2020;395(10231):1217-1224. doi:10.1016/S0140-6736(20)30611-5 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources